MCL prog list

Flow
Tutorial

Myeloproliferative neoplasms	Neoplasms with eosinophilia (PDGRA/PDGFRB/FGFR1)	MDS/MPN	MDS	AML	Acute leukemia ambiguous lineage
Precursor lymphoid neoplasms	Mature B cell neoplasms	Mature T and NK neoplasms	Hodgkin lymphoma	Immunodeficiency associated lymphoproliferative disorders	Histiocytic and dendritic cell neoplasms

Mantle Cell Lymphoma
	Unusual antigen expression abstracts	Prognostic abstracts	Cytogenetic abstracts	Antigen chart

B cell prolymphocytic leukemia

Splenic B cell marginal zone lymphoma

Hairy cell leukemia

Splenic B cell lymphoma / leukemia

Lymphoplasmacytic lymphoma

Heavy chain disease

Nodal marginal zone lymphoma

Primary cutaneous follicle center lymhoma

DLBCL associated with chronic inflammation

Lymphomatoid granulomatosis

Primary mediastinal large B cell lymphoma

Intravascular large B cell lymphoma

ALK positive large B cell lymphoma

Plasmablastic lymphoma

Large B cell lymphoma - HHV8 associated multicentric Castleman

Primary effusion lymphoma

Burkitt lymphoma

B cell lymphoma, unclassifiable with features of DLBCL and Burkitt

B cell lymphoma, unclassifiable with features of DLBCL and Hodgkin

Article	Notes
Miscellaneous studies
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.	Age, performance status, LDH and leukocyte count
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.	Ki-67, CD20